Pharmafile Logo

Pomalidomide Celgene

- PMLiVE

Biologics set to revolutionise the gastrointestinal market

Patent expirations and new approvals will see it grow to $48.4bn by 2020

National Institute for Health and Care Excellence NICE logo

AstraZeneca’s Forxiga set to be recommended by NICE

The type 2 diabetes ‘triple therapy’ is backed in draft guidance

Celgene building

Celgene bolsters blood cancer portfolio with $600m EngMab buy

Consolidates position as top company in current multiple myeloma market

- PMLiVE

Amgen’s Kyprolis scarred by head-to-head duel with Velcade

Failed to show superior progression-free survival in first-line treatment trials

- PMLiVE

Biogen launches Remicade biosimilar in the UK

Flixabi provides another low-cost alternative to J&J’s biggest-selling drug

- PMLiVE

Celgene disappointed as Revlimid fails lymphoma trial

Study shows improvement in progression-free survival but no overall survival rate benefit

Celgene building

Jounce bags $225m upfront in Celgene immuno-oncology deal

Five pipeline candidate agreement worth up to $2.5bn should Celgene claim the rights

- PMLiVE

Celgene’s Revlimid cleared for aggressive lymphoma type in EU

Analysts anticipate sales of up to $10bn for the newly-expanded drug in coming years

- PMLiVE

Amgen’s Kyprolis wins new indication in Europe

Regulators have handed the treatment a less restrictive licence in multiple myeloma 

- PMLiVE

Takeda hands back rights to two Amgen drugs

Returns pain and ovarian cancer candidates but will continue with collaboration

Celgene building

NICE rejects Celgene’s Vidaza for leukaemia

Final draft guidance cites ‘high degree of uncertainty’ over clinical efficacy

Celgene building

Celgene takes aim at cancer innovation with new US research consortium

Academic tie-up aims to develop new therapeutics and diagnostics

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links